{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T05:13:37Z","timestamp":1788066817481,"version":"build-2784847793"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ctrv.2020.102046","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T19:23:37Z","timestamp":1591212217000},"page":"102046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-6556","authenticated-orcid":false,"given":"Flora","family":"Zagouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Zoumpourlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Zografos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleoniki","family":"Apostolidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.102046_b0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review","volume":"28","author":"Dawood","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2020.102046_b0015","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1078-0432.CCR-06-2478","article-title":"Brain Metastases: The HER2 Paradigm","volume":"13","author":"Lin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102046_b0020","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3390\/ijms17071074","article-title":"Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions","volume":"17","author":"Lee","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2020.102046_b0025","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx221","article-title":"Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours\u2020","volume":"28","author":"le Rhun","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0030","unstructured":"National Comprehensive Cancer Network (NCCN).NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers Version 3.2019.2019 Oct 18; National Comprehensive Cancer Network. Abstract available at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf."},{"key":"10.1016\/j.ctrv.2020.102046_b0035","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noz126.070","article-title":"Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer","author":"le Rhun","year":"2019","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.ctrv.2020.102046_b0040","first-page":"561","article-title":"Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of","volume":"11","author":"Grossman","year":"1993","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ctrv.2020.102046_b0045","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.1987.5.10.1655","article-title":"A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis","volume":"5","author":"Hitchins","year":"1987","journal-title":"J Clin Oncol Off J American Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0050","first-page":"3394","article-title":"A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"5","author":"Glantz","year":"1999","journal-title":"Clin Cancer Res Off J American Association Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102046_b0055","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.ejca.2004.08.012","article-title":"The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study","volume":"40","author":"Boogerd","year":"2004","journal-title":"European J Cancer (Oxford, England 1990)"},{"issue":"18_suppl","key":"10.1016\/j.ctrv.2020.102046_b0060","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.1528","article-title":"A randomized phase III\/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis","volume":"24","author":"Shapiro","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0065","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11060-007-9420-5","article-title":"Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer","volume":"85","author":"Bartsch","year":"2007","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0070","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/annonc\/mdp353","article-title":"Trastuzumab treatment in patients with breast cancer and metastatic CNS disease","volume":"21","author":"Pienkowski","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood???brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ctrv.2020.102046_b0080","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.2000.18.11.2349","article-title":"Trastuzumab in CSF","volume":"18","author":"Pestalozzi","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ctrv.2020.102046_b0090","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-018-4684-3","article-title":"Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience","volume":"169","author":"Figura","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2020.102046_b0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2018.02.032","article-title":"Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis","volume":"95","author":"Bonneau","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102046_b0100","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.breast.2017.07.015","article-title":"Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience","volume":"36","author":"Kingston","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2020.102046_b0105","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s11523-016-0429-6","article-title":"Long-Term Survivor with Intrathecal and Intravenous Trastuzumab Treatment in Metastatic Breast Cancer","volume":"11","author":"Pluchart","year":"2016","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.breast.2015.11.005","article-title":"Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab","volume":"26","author":"Kordbacheh","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2020.102046_b0115","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4103\/0971-5851.190354","article-title":"Intrathecal trastuzumab for leptomeningeal carcinomatosis in patients with human epidermal growth factor receptor 2 positive breast cancer","volume":"37","author":"Gulia","year":"2016","journal-title":"Indian J Med Paediatric Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0120","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4143\/crt.2014.234","article-title":"Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis","volume":"48","author":"Park","year":"2016","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2020.102046_b0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40425-015-0084-y","article-title":"Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient","volume":"3","author":"Lu","year":"2015","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.ctrv.2020.102046_b0130","first-page":"1","article-title":"Intrathecal Trastuzumab Treatment of the Neoplastic Meningitis due to Breast Cancer: A Case Report and Review of the Literature","volume":"2013","author":"Dumitrescu","year":"2013","journal-title":"Case Rep Oncolog Med"},{"key":"10.1016\/j.ctrv.2020.102046_b0135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/0284186X.2012.689857","article-title":"Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases","volume":"52","author":"Martens","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0140","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.breast.2011.05.007","article-title":"Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis","volume":"20","author":"Mego","year":"2011","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2020.102046_b0145","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10549-011-1417-2","article-title":"Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab","volume":"127","author":"Oliveira","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2020.102046_b0150","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/annonc\/mdp019","article-title":"Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer","volume":"20","author":"Ferrario","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0155","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00280-008-0859-7","article-title":"Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab","volume":"63","author":"Colozza","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2020.102046_b0160","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/CAD.0b013e32830b58b0","article-title":"Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report","volume":"19","author":"Stemmler","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ctrv.2020.102046_b0165","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/annonc\/mdn654","article-title":"High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer","volume":"19","author":"Mir","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0170","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1470-2045(06)70864-6","article-title":"Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab","volume":"7","author":"Platini","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0175","doi-asserted-by":"crossref","DOI":"10.3892\/or.15.5.1373","article-title":"Application of intrathecal trastuzumab (HerceptinTM) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer","author":"Stemmler","year":"2006","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2020.102046_b0180","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1526-8209(11)70419-0","article-title":"Use of Intrathecal Trastuzumab in a Patient with Carcinomatous Meningitis","volume":"2","author":"Laufman","year":"2001","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2020.102046_b0185","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000375293","article-title":"Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases","volume":"8","author":"le Rhun","year":"2015","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0190","article-title":"Meningeosis carcinomatosa eines HER2-positiven","author":"Preusser","year":"2013","journal-title":"Mammakarzinoms"},{"key":"10.1016\/j.ctrv.2020.102046_b0195","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3109\/0284186X.2012.673736","article-title":"Intrathecal trastuzumab: dose matters","volume":"51","author":"Hofer","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0200","doi-asserted-by":"crossref","unstructured":"Allison DL, Glantz M, Werner TL et al (2009) Intra-CSF trastuzumab in patients with neoplastic meningitis from breast cancer or primary brain tumors. J Clin Oncol 27:Abstract 2066.","DOI":"10.1200\/jco.2009.27.15_suppl.2066"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2020.102046_b0205","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.1138","article-title":"Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer","volume":"26","author":"Shojima","year":"2008","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2020.102046_b0210","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3816\/CBC.2006.n.028","article-title":"Long-Term Clinical Response in Leptomeningeal Metastases from Breast Cancer Treated with Capecitabine Monotherapy: A Case Report","volume":"7","author":"Tham","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2020.102046_b0215","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1215\/S1152851703000334","article-title":"Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy","volume":"6","author":"Rogers","year":"2004","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0220","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1200\/JCO.2014.60.0353","volume":"33","author":"Lin","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0225","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102046_b0230","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-014-3054-z","article-title":"Leptomeningeal disease and breast cancer: the importance of tumor subtype","volume":"146","author":"Abouharb","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2020.102046_b0235","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1212\/01.WNL.0000160396.69050.DC","article-title":"Ventriculoperitoneal shunt in patients with leptomeningeal metastasis","volume":"64","author":"Omuro","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ctrv.2020.102046_b0240","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/A:1005982826121","article-title":"Radioisotope CSF flow studies in leptomeningeal metastases","volume":"38","author":"Chamberlain","year":"1998","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2020.102046_b0245","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/neuonc\/noz024","article-title":"The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal","volume":"21","author":"le Rhun","year":"2019","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.ctrv.2020.102046_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-012-1893-z","article-title":"Intra-CSF administration of chemotherapy medications","volume":"70","author":"Gabay","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2020.102046_b0255","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11060-011-0655-9","article-title":"The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis","volume":"106","author":"Brastianos","year":"2012","journal-title":"J Neurooncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:24:09Z","timestamp":1759656249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220300840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":51,"alternative-id":["S0305737220300840"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102046","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102046"}}